The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387
Pakzad F, Groves AM, Ell PJ (2006) The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36(3):248–256. https://doi.org/10.1053/j.semnuclmed.2006.03.005
Yeh R, Steinman J, Luk L, Kluger MD, Hecht EM (2017) Imaging of pancreatic cancer: what the surgeon wants to know. Clin Imaging 42:203–217. https://doi.org/10.1016/j.clinimag.2016.10.002
Cascinu S, Falconi M, Valentini V, Jelic S, Group EGW (2010) Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v55–58. https://doi.org/10.1093/annonc/mdq165
Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, Group EGW (2012) Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii33–40. https://doi.org/10.1093/annonc/mds224
Hillner BE, Siegel BA, Shields AF, et al. (2008) Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the national oncologic PET registry. J Nucl Med 49(12):1928–1935. https://doi.org/10.2967/jnumed.108.056713
Halbrook CJ, Lyssiotis CA (2017) Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell 31(1):5–19. https://doi.org/10.1016/j.ccell.2016.12.006
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033. https://doi.org/10.1126/science.1160809
Zimny M, Bares R, Fass J, et al. (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24(6):678–682
Dibble EH, Karantanis D, Mercier G, et al. (2012) PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol 199(5):952–967. https://doi.org/10.2214/AJR.11.8182
Best LM, Rawji V, Pereira SP, Davidson BR, Gurusamy KS (2017) Imaging modalities for characterising focal pancreatic lesions. Cochrane Database Syst Rev 4:CD010213. https://doi.org/10.1002/14651858.CD010213.pub2
Murakami K (2011) FDG-PET for hepatobiliary and pancreatic cancer: advances and current limitations. World J Clin Oncol 2(5):229–236. https://doi.org/10.5306/wjco.v2.i5.229
Delbeke D, Rose DM, Chapman WC, et al. (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40(11):1784–1791
Kauhanen SP, Komar G, Seppanen MP, et al. (2009) A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250(6):957–963. https://doi.org/10.1097/SLA.0b013e3181b2fafa
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD (1999) 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 229 (5):729–737; discussion 737–728
Stollfuss JC, Glatting G, Friess H, et al. (1995) 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 195(2):339–344. https://doi.org/10.1148/radiology.195.2.7724750
Evan GI, Hah N, Littlewood TD, et al. (2017) Re-engineering the pancreas tumor microenvironment: A “Regenerative Program” Hacked. Clin Cancer Res 23(7):1647–1655. https://doi.org/10.1158/1078-0432.CCR-16-3275
Ozaki Y, Oguchi K, Hamano H, et al. (2008) Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography. J Gastroenterol 43(2):144–151. https://doi.org/10.1007/s00535-007-2132-y
Lee TY, Kim MH, Park DH, et al. (2009) Utility of 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR Am J Roentgenol 193(2):343–348. https://doi.org/10.2214/AJR.08.2297
Lyall A, Vargas HA, Carvajal RD, Ulaner G (2012) Ipilimumab-induced colitis on FDG PET/CT. Clin Nucl Med 37(6):629–630. https://doi.org/10.1097/RLU.0b013e318248549a
Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82–92. https://doi.org/10.1007/s11102-015-0671-4
Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48(6):932–945. https://doi.org/10.2967/jnumed.106.035774
Soriano A, Castells A, Ayuso C, et al. (2004) Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography. Am J Gastroenterol 99(3):492–501. https://doi.org/10.1111/j.1572-0241.2004.04087.x
Wang Z, Chen JQ, Liu JL, Qin XG, Huang Y (2013) FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: a meta-analysis. World J Gastroenterol 19(29):4808–4817. https://doi.org/10.3748/wjg.v19.i29.4808
Barina AR, Bashir MR, Howard BA, et al. (2016) Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (NY) 41(2):207–214. https://doi.org/10.1007/s00261-015-0560-3
Wakabayashi H (2008) Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 14(1):64. https://doi.org/10.3748/wjg.14.64
Jain RK, Lee JJ, Ng C, et al. (2012) Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30(21):2684–2690
Sen N, Falk S, Abrams RA (2014) Role of chemoradiotherapy in the adjuvant and neoadjuvant settings for resectable pancreatic cancer. Clin Oncol (R Coll Radiol) 26(9):551–559. https://doi.org/10.1016/j.clon.2014.06.003
Topkan E, Yavuz AA, Aydin M, et al. (2008) Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res 27:41. https://doi.org/10.1186/1756-9966-27-41
Yoshioka M, Sato T, Furuya T, et al. (2004) Role of positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol 39(1):50–55. https://doi.org/10.1007/s00535-003-1244-2
Heinrich S, Schafer M, Weber A, et al. (2008) Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 248(6):1014–1022. https://doi.org/10.1097/SLA.0b013e318190a6da
Choi M, Heilbrun LK, Venkatramanamoorthy R, et al. (2010) Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol 33(3):257–261. https://doi.org/10.1097/COC.0b013e3181a76a0b
Sperti C, Pasquali C, Bissoli S, et al. (2010) Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 14(1):131–140. https://doi.org/10.1007/s11605-009-1010-8
Cameron K, Golan S, Simpson W, et al. (2011) Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging 36(4):463–471. https://doi.org/10.1007/s00261-011-9729-6
Toesca DA, Pollom EL, Poullos PD, et al. (2017) Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Pract Radiat Oncol 7(2):120–125. https://doi.org/10.1016/j.prro.2016.09.002
Ruf J, Lopez Hanninen E, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5(2–3):266–272. https://doi.org/10.1159/000085281
Yamamoto T, Sugiura T, Mizuno T, et al. (2015) Preoperative FDG-PET predicts early recurrence and a poor prognosis after resection of pancreatic adenocarcinoma. Ann Surg Oncol 22(2):677–684. https://doi.org/10.1245/s10434-014-4046-2
Strobel K, Heinrich S, Bhure U, et al. (2008) Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 49(9):1408–1413. https://doi.org/10.2967/jnumed.108.051466
Buchs NC, Buhler L, Bucher P, et al. (2011) Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol 26(4):657–662. https://doi.org/10.1111/j.1440-1746.2010.06525.x
Ford EC, Herman J, Yorke E, Wahl RL (2009) 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med 50(10):1655–1665. https://doi.org/10.2967/jnumed.108.055780
Li XX, Liu NB, Zhu L, et al. (2015) Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer. Br J Radiol 88(1051):20140590. https://doi.org/10.1259/bjr.20140590
Heinrich S, Goerres GW, Schafer M, et al. (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242(2):235–243
Kamisawa T, Takum K, Anjiki H, et al. (2010) FDG-PET/CT findings of autoimmune pancreatitis. Hepato-gastroenterology 57(99–100):447–450
Kato K, Nihashi T, Ikeda M, et al. (2013) Limited efficacy of 18F-FDG PET/CT for differentiation between metastasis-free pancreatic cancer and mass-forming pancreatitis. Clin Nucl Med 38(6):417. https://doi.org/10.1097/rlu.0b013e3182817d9d
Matsumoto I, Shirakawa S, Shinzeki M, et al. (2013) 18-Fluorodeoxyglucose positron emission tomography does not aid in diagnosis of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol 11(6):712–718. https://doi.org/10.1016/j.cgh.2012.12.033
Rijkers AP, Valkema R, Duivenvoorden HJ, van Eijck CHJ (2014) Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer: a meta-analysis. Eur J Surg Oncol (EJSO) 40(7):794–804. https://doi.org/10.1016/j.ejso.2014.03.016
Attenberger U, Catana C, Chandarana H, et al. (2015) Whole-body FDG PET-MR oncologic imaging: pitfalls in clinical interpretation related to inaccurate MR-based attenuation correction. Abdom Imaging 40(6):1374–1386. https://doi.org/10.1007/s00261-015-0455-3
Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA (2012) State-of-the-Art PET/CT of the pancreas: current role and emerging indications. Radiographics 32(4):1133–1158. https://doi.org/10.1148/rg.324115143
Katz MHG, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749–5756. https://doi.org/10.1002/cncr.27636
Lee D, Kim S, Im S-A, et al. (2015) Multiparametric fully-integrated 18-FDG PET/MRI of advanced gastric cancer for prediction of chemotherapy response: a preliminary study. Eur Radiol 26(8):2771–2778. https://doi.org/10.1007/s00330-015-4105-5
Broski Johnson GB, Goenka AH (2017) Gastrointestinal: Multiparametric hybrid 18-FDG PET/MRI evaluation of gastric adenocarcinoma. J Gastroenterol Hepatol 32(6):1132–1132. https://doi.org/10.1111/jgh.13631
Kittaka H, Takahashi H, Ohigashi H, et al. (2013) Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J Surg 37(1):169–178. https://doi.org/10.1007/s00268-012-1775-x
Cuneo KC, Chenevert TL, Ben-Josef E, et al. (2014) A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer. Transl Oncol 7(5):644–649. https://doi.org/10.1016/j.tranon.2014.07.005
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S
Raman SP, Chen Y, Fishman EK (2015) Cross-sectional imaging and the role of positron emission tomography in pancreatic cancer evaluation. Semin Oncol 42(1):40–58. https://doi.org/10.1053/j.seminoncol.2014.12.005
Wang X-Y, Yang F, Jin C, Fu D-L (2014) Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 20(42):15580–15589. https://doi.org/10.3748/wjg.v20.i42.15580
Pakzad F, Groves AM, Ell PJ (2006) The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36(3):248–256. https://doi.org/10.1053/j.semnuclmed.2006.03.005
Liu RC, Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 19(5):638–642. https://doi.org/10.1007/s00464-004-8165-x
Izuishi K, Yamamoto Y, Sano T, et al. (2010) Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer. J Gastrointest Surg 14(7):1151–1158. https://doi.org/10.1007/s11605-010-1207-x
Lytras D, Connor S, Bosonnet L, et al. (2005) Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 22(1–2):55–62. https://doi.org/10.1159/000085347
Bang S, Chung H, Park S, et al. (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40(10):923. https://doi.org/10.1097/01.mcg.0000225672.68852.05
Farma JM, Santillan AA, Melis M, et al. (2008) PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 15(9):2465–2471. https://doi.org/10.1245/s10434-008-9992-0
Sperti C, Pasquali C, Bissoli S, et al. (2010) Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg 14(1):131–140. https://doi.org/10.1007/s11605-009-1010-8
Ruf J, Hänninen LE, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5(2–3):266–272. https://doi.org/10.1159/000085281
Chen F-M, Ni J-M, Zhang Z-Y, et al. (2016) Presurgical evaluation of pancreatic cancer: a comprehensive imaging comparison of CT versus MRI. AJR Amer J Roentgenol 206(3):526–535. https://doi.org/10.2214/ajr.15.15236
Joo I, Lee J, Lee D, et al. (2016) Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology 282(1):152798. https://doi.org/10.1148/radiol.2016152798
Im HJ, Oo S, Jung W, et al. (2016) Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer. Med (Baltimore) 95(19):e3686. https://doi.org/10.1097/MD.0000000000003686
Lee J, Kang C, Choi H, et al. (2014) Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with pancreatic cancer. J Nucl Med 55(6):898–904. https://doi.org/10.2967/jnumed.113.131847
Choi HJ, Lee JW, Kang B, et al. (2014) Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy. Yonsei Med J 55(6):1498–1506. https://doi.org/10.3349/ymj.2014.55.6.1498
Pimiento JM, Davis-Yadley AH, Kim RD, et al. (2016) Metabolic activity by 18F-FDG-PET/CT is prognostic for stage I and II pancreatic cancer. Clin Nucl Med 41(3):177–181. https://doi.org/10.1097/RLU.0000000000001098
Schellenberg D, Quon A, Minn AY, et al. (2010) 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 77(5):1420–1425. https://doi.org/10.1016/j.ijrobp.2009.06.049
Moon SY, Joo KR, So YR, et al. (2013) Predictive value of maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT in patients with locally advanced or metastatic pancreatic cancer. Clin Nucl Med 38(10):778–783. https://doi.org/10.1097/RLU.0b013e31829f8c90
Topkan E, Parlak C, Kotek A, Yapar AF, Pehlivan B (2011) Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol 11:123. https://doi.org/10.1186/1471-230X-11-123
Kuwatani M, Kawakami H, Eto K, et al. (2009) Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 48(11):867–875
Sheikhbahaei S, Wray R, Young B, et al. (2016) 18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma: impact on management and utilization of quantitative parameters for patient survival prediction. Nucl Med Commun 37(3):231–238. https://doi.org/10.1097/MNM.0000000000000436